Lakewood-Amedex Backs PASTEUR Act Reintroduction as It Preps Phase 2 Trial for Diabetic Foot Ulcer Treatment
Event summary
- Lakewood-Amedex Biotherapeutics supports the reintroduction of the bipartisan PASTEUR Act to combat antimicrobial resistance (AMR).
- The company's Bisphosphocin® platform targets resistant bacterial strains like MRSA and VRE through membrane destabilization.
- Lead candidate Nu-3 is preparing for Phase 2 trials as a topical treatment for infected diabetic foot ulcers (iDFU).
- iDFUs affect millions globally, often leading to hospitalization or amputation if untreated.
The big picture
Lakewood-Amedex's support for the PASTEUR Act underscores the growing urgency in addressing antimicrobial resistance, a threat that could undermine modern healthcare. The company's Bisphosphocin® platform represents a novel approach in an industry increasingly focused on combating superbugs. With Nu-3 poised to enter Phase 2 trials, success could position Lakewood-Amedex as a key player in the fight against resistant infections.
What we're watching
- Regulatory Tailwinds
- How the PASTEUR Act's reintroduction could accelerate development timelines for novel antimicrobials.
- Clinical Execution
- Whether Nu-3 can demonstrate efficacy in Phase 2 trials to address the unmet need in iDFU treatment.
- Resistance Dynamics
- The pace at which Bisphosphocin®'s mechanism may reduce resistance development compared to existing antibiotics.
Related topics